Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno-Therapy.
T cells
copper‐64
immune checkpoint therapy
immunotherapy
iodine‐124
isotope labeling
noninvasive monitoring
solid target
zirconium‐89
Journal
Journal of labelled compounds & radiopharmaceuticals
ISSN: 1099-1344
Titre abrégé: J Labelled Comp Radiopharm
Pays: England
ID NLM: 7610510
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
revised:
07
08
2024
received:
26
04
2024
accepted:
07
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
aheadofprint
Résumé
Immune checkpoint therapy has emerged as an effective treatment option for various types of cancers. Key immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and lymphocyte activation gene 3 (LAG-3), have become pivotal targets in cancer immunotherapy. Antibodies designed to inhibit these molecules have demonstrated significant clinical efficacy. Nevertheless, the ability to monitor changes in the immune status of tumors and predict treatment response remains limited. Conventional methods, such as assessing lymphocytes in peripheral blood or conducting tumor biopsies, are inadequate for providing real-time, spatial information about T-cell distributions within heterogeneous tumors. Positron emission tomography (PET) using T-cell specific probes represents a promising and noninvasive approach to monitor both systemic and intratumoral immune changes during treatment. This technique holds substantial clinical significance and potential utility. In this paper, we review the applications of PET probes that target immune cells in molecular imaging.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
P. P. van de Donk, S. F. Oosting, D. G. Knapen, et al., “Molecular Imaging to Support Cancer Immunotherapy,” Journal for Immunotherapy of Cancer 10, no. 8 (2022): e004949.
K. M. Mahoney, P. D. Rennert, and G. J. Freeman, “Combination Cancer Immunotherapy and New Immunomodulatory Targets,” Nature Reviews. Drug Discovery 14, no. 8 (2015): 561–584.
F. Kraeber‐Bodere, C. Bailly, M. Chérel, and J.‐F. Chatal, “ImmunoPET to Help Stratify Patients for Targeted Therapies and to Improve Drug Development,” European Journal of Nuclear Medicine and Molecular Imaging 43, no. 12 (2016): 2166–2168.
S. Rossi, L. Toschi, A. Castello, F. Grizzi, L. Mansi, and E. Lopci, “Clinical Characteristics of Patient Selection and Imaging Predictors of Outcome in Solid Tumors Treated With Checkpoint‐Inhibitors,” European Journal of Nuclear Medicine and Molecular Imaging 44, no. 13 (2017): 2310–2325.
W. Wei, D. Jiang, E. B. Ehlerding, Q. Luo, and W. Cai, “Noninvasive PET Imaging of T Cells,” Trends Cancer 4, no. 5 (2018): 359–373.
T. J. Wadas, E. H. Wong, G. R. Weisman, and C. J. Anderson, “Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease,” Chemical Reviews 110, no. 5 (2010): 2858–2902.
L. Jødal, C. Le Loirec, and C. Champion, “Positron Range in PET Imaging: Non‐Conventional Isotopes,” Physics in Medicine and Biology 59, no. 23 (2014): 7419–7434.
M. A. Avila‐Rodriguez, J. A. Nye, and R. J. Nickles, “Simultaneous Production of High Specific Activity 64Cu and 61Co With 11.4 MeV Protons on Enriched 64Ni Nuclei,” Applied Radiation and Isotopes 65, no. 10 (2007): 1115–1120.
X. Hou, U. Jacobsen, and J. C. Jørgensen, “Separation of No‐Carrier‐Added 64Cu From a Proton Irradiated 64Ni Enriched Nickel Target,” Applied Radiation and Isotopes 57, no. 6 (2002): 773–777.
J. R. Ometáková, P. Rajec, V. Csiba, et al., “Automated Production of ~(64)Cu Prepared by 18 MeV Cyclotron,” Journal of Radioanalytical and Nuclear Chemistry: An International Journal Dealing With all Aspects and Applications of Nuclear Chemistry 293, no. 1 (2012): 217–222.
L. Daraban, K. Abbas, F. Simonelli, R. Adam‐Rebeles, and N. Gibson, “Experimental Study of Excitation Functions for the Deuteron Induced Reactions 64Zn(D,2p)64Cu and 64Zn(D,Alphan)61Cu Using the Stacked‐Foil Technique,” Applied Radiation and Isotopes 66, no. 2 (2008): 261–264.
I. M. Cohen, M. C. Fornaciari Iljadica, J. C. Furnari, and M. C. Alí Santoro, “The Consistency of the Data for Neutron Fission Averaged Cross‐Sections of Threshold Reactions: A Study on the Cross‐Section of 46Ti(N,p)46Sc, 47Ti(N,p)47Sc, 48Ti(N,p)48Sc and 64Zn(N,p)64Cu Reactions,” Applied Radiation and Isotopes 77 (2013): 115–129.
B. J. B. Nelson, S. Leier, J. Wilson, et al., “64Cu Production via the 68Zn(P,nα)64Cu Nuclear Reaction: An Untapped, Cost‐Effective and High Energy Production Route,” Nuclear Medicine and Biology 128‐129 (2024): 108875.
J. P. Holland, Y. Sheh, and J. S. Lewis, “Standardized Methods for the Production of High Specific‐Activity Zirconium‐89,” Nuclear Medicine and Biology 36, no. 7 (2009): 729–739.
Y. Tang, S. Li, Y. Yang, et al., “A Simple and Convenient Method for Production of 89Zr With High Purity,” Applied Radiation and Isotopes 118 (2016): 326–330.
J. Schmitz, “The Production of [124I]Iodine and [86Y]Yttrium,” European Journal of Nuclear Medicine and Molecular Imaging 38, no. Suppl 1 (2011): S4–S9.
K. Nagatsu, M. Fukada, K. Minegishi, et al., “Fully Automated Production of Iodine‐124 Using a Vertical Beam,” Applied Radiation and Isotopes 69, no. 1 (2011): 146–157.
S. M. Qaim, A. Hohn, T. Bastian, et al., “Some Optimisation Studies Relevant to the Production of High‐Purity 124I and 120gI at a Small‐Sized Cyclotron,” Applied Radiation and Isotopes 58, no. 1 (2003): 69–78.
M. Sajjad, E. Bars, and H. A. Nabi, “Optimization of 124I Production via 124Te(P,n)124I Reaction,” Applied Radiation and Isotopes 64, no. 9 (2006): 965–970.
K. Kondo, R. M. Lambrecht, E. F. Norton, and A. P. Wolf, “Cyclotron Isotopes and Radiopharmaceuticals—XXII. Improved Targetry and Radiochemistry for Production of 123I and 124I,” International Journal of Applied Radiation and Isotopes 28, no. 9 (1977): 765–771.
T. H. Bastian, H. H. Coenen, and S. M. Qaim, “Excitation Functions of 124Te(D,xn)124,125I Reactions From Threshold up to 14MeV: Comparative Evaluation of Nuclear Routes for the Production of 124I,” Applied Radiation and Isotopes 55, no. 3 (2001): 303–308.
R. van den Bosch, J. J. De Goeij, J. A. Van der Heide, J. F. Tertoolen, H. M. Theelen, and C. Zegers, “A New Approach to Target Chemistry for the Iodine‐123 Production via the 124Te(P, 2n) Reaction,” International Journal of Applied Radiation and Isotopes 28, no. 3 (1977): 255–261.
A. Hohn, F. M. Nortier, B. Scholten, T. N. van der Walt, H. H. Coenen, and S. M. Qaim, “Excitation Functions of 125Te(P, xn)‐Reactions From Their Respective Thresholds up to 100 MeV With Special Reference to the Production of 124I,” Applied Radiation and Isotopes 55, no. 2 (2001): 149–156.
K. F. Hassan, S. M. Qaim, Z. A. Saleh, and H. H. Coenen, “3He‐Particle‐Induced Reactions on (Nat)Sb for Production of 124I,” Applied Radiation and Isotopes 64, no. 4 (2006): 409–413.
M. S. Uddin, A. Hermanne, S. Sudár, et al., “Excitation Functions of α‐Particle Induced Reactions on Enriched 123Sb and (Nat)Sb for Production of 124I,” Applied Radiation and Isotopes 69, no. 4 (2011): 699–704.
E. Aluicio‐Sarduy, P. A. Ellison, T. E. Barnhart, W. Cai, R. J. Nickles, and J. W. Engle, “PET Radiometals for Antibody Labeling,” Journal of Labelled Compounds and Radiopharmaceuticals 61, no. 9 (2018): 636–651.
W. Cai, Y. Wu, K. Chen, Q. Cao, D. A. Tice, and X. Chen, “In Vitro and in Vivo Characterization of 64Cu‐Labeled Abegrin, a Humanized Monoclonal Antibody Against Integrin Alpha v Beta 3,” Cancer Research 66, no. 19 (2006): 9673–9681.
W. Cai, K. Chen, L. He, Q. Cao, A. Koong, and X. Chen, “Quantitative PET of EGFR Expression in Xenograft‐Bearing Mice Using 64Cu‐Labeled Cetuximab, a Chimeric Anti‐EGFR Monoclonal Antibody,” European Journal of Nuclear Medicine and Molecular Imaging 34, no. 6 (2007): 850–858.
K. Tamura, H. Kurihara, K. Yonemori, et al., “64Cu‐DOTA‐Trastuzumab PET Imaging in Patients With HER2‐Positive Breast Cancer,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 54, no. 11 (2013): 1869–1875.
M. Moreau, S. Poty, J. M. Vrigneaud, et al., “MANOTA: A Promising Bifunctional Chelating Agent for Copper‐64 ImmunoPET,” Dalton Transactions 46, no. 42 (2017): 14659–14668.
L. Jiang, Y. Tu, R. H. Kimura, et al., “64Cu‐Labeled Divalent Cystine Knot Peptide for Imaging Carotid Atherosclerotic Plaques,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 56, no. 6 (2015): 939–944.
S.‐K. Woo, S. J. Jang, M.‐J. Seo, et al., “Development of 64Cu‐NOTA‐Trastuzumab for HER2 Targeting: A Radiopharmaceutical With Improved Pharmacokinetics for Human Studies,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 60, no. 1 (2019): 26–33.
S. C. Ghosh, K. L. Pinkston, H. Robinson, et al., “Comparison of DOTA and NODAGA as Chelators for 64Cu‐Labeled Immunoconjugates,” Nuclear Medicine and Biology 42, no. 2 (2015): 177–183.
S. R. Banerjee, M. Pullambhatla, C. A. Foss, et al., “64Cu‐Labeled Inhibitors of Prostate‐Specific Membrane Antigen for PET Imaging of Prostate Cancer,” Journal of Medicinal Chemistry 57, no. 6 (2014): 2657–2669.
R. Ferdani, D. J. Stigers, A. L. Fiamengo, et al., “Synthesis, Cu (II) Complexation, 64Cu‐Labeling and Biological Evaluation of Cross‐Bridged Cyclam Chelators With Phosphonate Pendant Arms,” Dalton Transactions 41, no. 7 (2012): 1938–1950.
M. D. Farwell, R. F. Gamache, H. Babazada, et al., “CD8‐Targeted PET Imaging of Tumor‐Infiltrating T Cells in Patients With Cancer: A Phase I First‐In‐Humans Study of Zr‐Df‐IAB22M2C, a Radiolabeled Anti‐CD8 Minibody,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 63, no. 5 (2022): 720–726.
I. J. G. Burvenich, Y. W. Goh, N. Guo, et al., “Radiolabelling and Preclinical Characterization of 89Zr‐Df‐Radiolabelled Bispecific Anti‐PD‐L1/TGF‐βRII Fusion Protein Bintrafusp Alfa,” European Journal of Nuclear Medicine and Molecular Imaging 48, no. 10 (2021): 3075–3088.
M. J. W. D. Vosjan, L. R. Perk, G. W. M. Visser, et al., “Conjugation and Radiolabeling of Monoclonal Antibodies With Zirconium‐89 for PET Imaging Using the Bifunctional Chelate p‐Isothiocyanatobenzyl‐Desferrioxamine,” Nature Protocols 5, no. 4 (2010): 739–743.
L. R. Perk, M. J. W. D. Vosjan, G. W. M. Visser, et al., “p‐Isothiocyanatobenzyl‐Desferrioxamine: A New Bifunctional Chelate for Facile Radiolabeling of Monoclonal Antibodies With Zirconium‐89 for Immuno‐PET Imaging,” European Journal of Nuclear Medicine and Molecular Imaging 37, no. 2 (2010): 250–259.
H. Hong, G. W. Severin, Y. Yang, et al., “Positron Emission Tomography Imaging of CD105 Expression With 89Zr‐Df‐TRC105,” European Journal of Nuclear Medicine and Molecular Imaging 39, no. 1 (2012): 138–148.
Y. Chen, X. Hou, D. Li, et al., “Development of a CLDN18.2‐Targeting Immuno‐PET Probe for Non‐Invasive Imaging in Gastrointestinal Tumors,” Journal of Pharmaceutical Analysis 13, no. 4 (2023): 367–375.
W. Wei, Z. T. Rosenkrans, J. Liu, G. Huang, Q.‐Y. Luo, and W. Cai, “ImmunoPET: Concept, Design, and Applications,” Chemical Reviews 120, no. 8 (2020): 3787–3851.
I. Verel, G. W. M. Visser, and G. A. van Dongen, “The Promise of Immuno‐PET in Radioimmunotherapy,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 46, no. Suppl 1 (2005): 164S–171S.
C. B. Wilson, D. E. Snook, B. Dhokia, et al., “Quantitative Measurement of Monoclonal Antibody Distribution and Blood Flow Using Positron Emission Tomography and 124iodine in Patients With Breast Cancer,” International Journal of Cancer 47, no. 3 (1991): 344–347.
J. P. Holland, M. J. Williamson, and J. S. Lewis, “Unconventional Nuclides for Radiopharmaceuticals,” Molecular Imaging 9 (2010): 1–20.
I. Guenther, L. Wyer, E. J. Knust, R. D. Finn, J. Koziorowski, and R. Weinreich, “Radiosynthesis and Quality Assurance of 5‐[124I]Iodo‐2′‐Deoxyuridine for Functional PET Imaging of Cell Proliferation,” Nuclear Medicine and Biology 25, no. 4 (1998): 359–365.
S. K. Pandey, A. L. Gryshuk, M. Sajjad, et al., “Multimodality Agents for Tumor Imaging (PET, Fluorescence) and Photodynamic Therapy. A Possible “See and Treat” Approach,” Journal of Medicinal Chemistry 48, no. 20 (2005): 6286–6295.
Y. Cheng, D. Shi, R. Ye, et al., “Noninvasive Evaluation of PD‐L1 Expression in Non‐Small Cell Lung Cancer by ImmunoPET Imaging Using an Acylating Agent‐Modified Antibody Fragment,” European Journal of Nuclear Medicine and Molecular Imaging 50, no. 6 (2023): 1585–1596.
X. Hou, F. Wang, X. Meng, et al., “Construction of a 124I‐Labeled Specific Antibody for the Noninvasive Detection of Mesothelin‐Overexpressing Tumors,” Molecular Pharmaceutics 19, no. 10 (2022): 3623–3631.
D. Li, J. Ding, T.‐L. Liu, et al., “SARS‐CoV‐2 Receptor Binding Domain Radio‐Probe: A Non‐Invasive Approach for Angiotensin‐Converting Enzyme 2 Mapping in Mice,” Acta Pharmacologica Sinica 43, no. 7 (2022): 1749–1757.
Y. Yao, X. Hou, S. Liu, et al., “Construction and Preclinical Evaluation of a 124/125I‐Labeled Specific Antibody Targeting PD‐L2 in Lung Cancer,” Molecular Pharmaceutics 20, no. 2 (2023): 1365–1374.
D. Li, F. Wang, J. Jiang, et al., “Construction of an Iodine‐Labeled CS1001 Antibody for Targeting PD‐L1 Detection and Comparison With Low‐Molecular‐Peptide Micro‐PET Imaging,” Molecular Pharmaceutics 19, no. 11 (2022): 4382–4389.
N. Aide, C. Lasnon, C. Desmonts, I. S. Armstrong, M. D. Walker, and D. R. McGowan, “Advances in PET/CT Technology: An Update,” Seminars in Nuclear Medicine 52, no. 3 (2022): 286–301.
A. Rahmim, M. A. Lodge, N. A. Karakatsanis, et al., “Dynamic Whole‐Body PET Imaging: Principles, Potentials and Applications,” European Journal of Nuclear Medicine and Molecular Imaging 46, no. 2 (2019): 501–518.
Q. Xie, H. Zhu, F. Wang, et al., “Establishing Reliable Cu‐64 Production Process: From Target Plating to Molecular Specific Tumor Micro‐PET Imaging,” Molecules 22, no. 4 (2017): 641.
M. T. La, V. H. Tran, and H.‐K. Kim, “Progress of Coordination and Utilization of Zirconium‐89 for Positron Emission Tomography (PET) Studies,” Nuclear Medicine and Molecular Imaging 53, no. 2 (2019): 115–124.
M. K. Pandey, H. P. Engelbrecht, J. P. Byrne, A. B. Packard, and T. R. DeGrado, “Production of 89Zr via the 89Y(P,n)89Zr Reaction in Aqueous Solution: Effect of Solution Composition on In‐Target Chemistry,” Nuclear Medicine and Biology 41, no. 4 (2014): 309–316.
A. Kasbollah, P. Eu, S. Cowell, and P. Deb, “Review on Production of 89Zr in a Medical Cyclotron for PET Radiopharmaceuticals,” Journal of Nuclear Medicine Technology 41, no. 1 (2013): 35–41.
M. K. Pandey, A. Bansal, H. P. Engelbrecht, J. F. Byrne, A. B. Packard, and T. R. DeGrado, “Improved Production and Processing of 89Zr Using a Solution Target,” Nuclear Medicine and Biology 43, no. 1 (2016): 97–100.
F. Wang, J. Ding, X. Guo, et al., “Production of the Next‐Generation Positron Nuclide Zirconium‐89 (89Zr) Guided by Monte Carlo Simulation and Its Good Quality for Antibody Labeling,” Journal of Labelled Compounds and Radiopharmaceuticals 64, no. 1 (2021): 47–56.
F. Wang, T. Liu, L. Li, et al., “Production, Quality Control of Next‐Generation PET Radioisotope Iodine‐124 and Its Thyroid Imaging,” Journal of Radioanalytical and Nuclear Chemistry 318, no. 1 (2018): 1999–2006.
K. Dobrenkov, M. Olszewska, Y. Likar, et al., “Monitoring the Efficacy of Adoptively Transferred Prostate Cancer‐Targeted Human T Lymphocytes With PET and Bioluminescence Imaging,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 49, no. 7 (2008): 1162–1170.
D. Pan, G. Li, H. Hu, et al., “Direct Immunoassay for Facile and Sensitive Detection of Small Molecule Aflatoxin B1 Based on Nanobody,” Chemistry 24, no. 39 (2018): 9869–9876.
S. Krah, C. Sellmann, L. Rhiel, et al., “Engineering Bispecific Antibodies With Defined Chain Pairing,” New Biotechnology 39, no. Pt B (2017): 167–173.
J. Buxbaum, E. C. Franklin, and M. D. Scharff, “Immunoglobulin M Heavy Chain Disease: Intracellular Origin of the Mu Chain Fragment,” Science 169, no. 3947 (1970): 770–773.
G. Spira, I. Silvian, I. Tatarsky, and A. Carter, “Detection of IgD “Hidden” Lambda Light Chain,” Journal of Immunological Methods 60, no. 1‐2 (1983): 207–212.
J. L. Atwell, J. J. Marchalonis, and E. H. Ealey, “Major Immunoglobulin Classes of the Echidna (Tachyglossus aculeatus),” Immunology 25, no. 5 (1973): 835–846.
S. Kittipongwarakarn, A. Hawe, R. Tantipolphan, et al., “New Method to Produce Equine Antirabies Immunoglobulin F (ab′)₂ Fragments From Crude Plasma in High Quality and Yield,” European Journal of Pharmaceutics and Biopharmaceutics 78, no. 2 (2011): 189–195.
E. B. Ehlerding, C. G. England, R. L. Majewski, et al., “ImmunoPET Imaging of CTLA‐4 Expression in Mouse Models of Non‐Small Cell Lung Cancer,” Molecular Pharmaceutics 14, no. 5 (2017): 1782–1789.
E. B. Ehlerding, H. J. Lee, D. Jiang, et al., “Antibody and Fragment‐Based PET Imaging of CTLA‐4+ T‐Cells in Humanized Mouse Models,” American Journal of Cancer Research 9, no. 1 (2019): 53–63.
K. Higashikawa, K. Yagi, K. Watanabe, et al., “64Cu‐DOTA‐Anti‐CTLA‐4 mAb Enabled PET Visualization of CTLA‐4 on the T‐Cell Infiltrating Tumor Tissues,” PLoS ONE 9, no. 11 (2014): e109866.
I. H. Miedema, G. J. Zwezerijnen, G. A. Dongen, et al., “Abstract 1136: Tumor Uptake and Biodistribution of 89Zirconium‐Labeled Ipilimumab in Patients With Metastatic Melanoma During Ipilimumab Treatment,” Cancer Research 79, no. 13_Supplement (2019): 1136.
S. J. Dovedi, M. J. Elder, C. Yang, et al., “Design and Efficacy of a Monovalent Bispecific PD‐1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD‐1+ Activated T Cells,” Cancer Discovery 11, no. 5 (2021): 1100–1117.
A. Natarajan, A. T. Mayer, L. Xu, R. E. Reeves, J. Gano, and S. S. Gambhir, “Novel Radiotracer for ImmunoPET Imaging of PD‐1 Checkpoint Expression on Tumor Infiltrating Lymphocytes,” Bioconjugate Chemistry 26, no. 10 (2015): 2062–2069.
C. G. England, E. B. Ehlerding, R. Hernandez, et al., “Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr‐Labeled Pembrolizumab,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 58, no. 1 (2017): 162–168.
E. L. van der Veen, D. Giesen, L. Pot‐de Jong, A. Jorritsma‐Smit, E. G. E. de Vries, and M. N. Lub‐de Hooge, “89Zr‐Pembrolizumab Biodistribution Is Influenced by PD‐1‐Mediated Uptake in Lymphoid Organs,” Journal for Immunotherapy of Cancer 8, no. 2 (2020): e000938.
W. Li, Y. Wang, D. Rubins, et al., “PET/CT Imaging of 89Zr‐N‐sucDf‐Pembrolizumab in Healthy Cynomolgus Monkeys,” Molecular Imaging and Biology 23, no. 2 (2021): 250–259.
I. C. Kok, J. S. Hooiveld, P. P. van de Donk, et al., “89Zr‐Pembrolizumab Imaging as a Non‐Invasive Approach to Assess Clinical Response to PD‐1 Blockade in Cancer,” Annals of Oncology 33, no. 1 (2022): 80–88.
A. N. Niemeijer, D. Leung, M. C. Huisman, et al., “Whole Body PD‐1 and PD‐L1 Positron Emission Tomography in Patients With Non‐Small‐Cell Lung Cancer,” Nature Communications 9, no. 1 (2018): 4664.
H. Huang, H. Zhu, Q. Xie, et al., “Evaluation of I‐JS001 for hPD1 Immuno‐PET Imaging Using Sarcoma Cell Homografts in Humanized Mice,” Acta Pharmaceutica Sinica B 10, no. 7 (2020): 1321–1330.
S. Wang, H. Zhu, J. Ding, et al., “Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I‐Labeled Toripalimab: A Pilot Clinical Translation Study,” Clinical Nuclear Medicine 46, no. 5 (2021): 382–388.
I. H. C. Miedema, M. C. Huisman, G. J. C. Zwezerijnen, et al., “89Zr‐Immuno‐PET Using the Anti‐LAG‐3 Tracer [89Zr]Zr‐BI 754111: Demonstrating Target Specific Binding in NSCLC and HNSCC,” European Journal of Nuclear Medicine and Molecular Imaging 50, no. 7 (2023): 2068–2080.
P. W. Rothlauf, Z. Li, N. Pishesha, et al., “Noninvasive Immuno‐PET Imaging of CD8+ T Cell Behavior in Influenza a Virus‐Infected Mice,” Frontiers in Immunology 12 (2021): 777739.
R. Tavaré, M. N. McCracken, K. A. Zettlitz, et al., “Immuno‐PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti‐CD4 and Anti‐CD8 Cys‐Diabodies,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 56, no. 8 (2015): 1258–1264.
A. C. Freise, K. A. Zettlitz, F. B. Salazar, et al., “Immuno‐PET in Inflammatory Bowel Disease: Imaging CD4‐Positive T Cells in a Murine Model of Colitis,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 59, no. 6 (2018): 980–985.
L. K. Kristensen, C. Fröhlich, C. Christensen, et al., “CD4+ and CD8a+ PET Imaging Predicts Response to Novel PD‐1 Checkpoint Inhibitor: Studies of Sym021 in Syngeneic Mouse Cancer Models,” Theranostics 9, no. 26 (2019): 8221–8238.
R. Tavaré, H. Escuin‐Ordinas, S. Mok, et al., “An Effective Immuno‐PET Imaging Method to Monitor CD8‐Dependent Responses to Immunotherapy,” Cancer Research 76, no. 1 (2016): 73–82.
J. W. Seo, R. Tavaré, L. M. Mahakian, et al., “CD8+ T‐Cell Density Imaging With 64Cu‐Labeled Cys‐Diabody Informs Immunotherapy Protocols,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 24, no. 20 (2018): 4976–4987.
L. Kist de Ruijter, P. P. van de Donk, J. S. Hooiveld‐Noeken, et al., “Whole‐Body CD8+ T Cell Visualization Before and During Cancer Immunotherapy: A Phase 1/2 Trial,” Nature Medicine 28, no. 12 (2022): 2601–2610.
S. Van Coillie, B. Wiernicki, and J. Xu, “Molecular and Cellular Functions of CTLA‐4,” Advances in Experimental Medicine and Biology 1248 (2020): 7–32.
E. L. Masteller, E. Chuang, A. C. Mullen, S. L. Reiner, and C. B. Thompson, “Structural Analysis of CTLA‐4 Function in Vivo,” Journal of Immunology 164, no. 10 (2000): 5319–5327.
J. J. Engelhardt, T. J. Sullivan, and J. P. Allison, “CTLA‐4 Overexpression Inhibits T Cell Responses Through a CD28‐B7‐Dependent Mechanism,” Journal of Immunology 177, no. 2 (2006): 1052–1061.
D. R. Leach, M. F. Krummel, and J. P. Allison, “Enhancement of Antitumor Immunity by CTLA‐4 Blockade,” Science 271, no. 5256 (1996): 1734–1736.
A. Gros, P. F. Robbins, X. Yao, et al., “PD‐1 Identifies the Patient‐Specific CD8+ Tumor‐Reactive Repertoire Infiltrating Human Tumors,” Journal of Clinical Investigation 124, no. 5 (2014): 2246–2259.
D. Davar, A. K. Dzutsev, J. A. McCulloch, et al., “Fecal Microbiota Transplant Overcomes Resistance to Anti‐PD‐1 Therapy in Melanoma Patients,” Science 371, no. 6529 (2021): 595–602.
R. S. Herbst, J.‐C. Soria, M. Kowanetz, et al., “Predictive Correlates of Response to the Anti‐PD‐L1 Antibody MPDL3280A in Cancer Patients,” Nature 515, no. 7528 (2014): 563–567.
X. Chen, X. Pan, W. Zhang, et al., “Epigenetic Strategies Synergize With PD‐L1/PD‐1 Targeted Cancer Immunotherapies to Enhance Antitumor Responses,” Acta Pharmaceutica Sinica B 10, no. 5 (2020): 723–733.
L. Ni and C. Dong, “New B7 Family Checkpoints in Human Cancers,” Molecular Cancer Therapeutics 16, no. 7 (2017): 1203–1211.
L. P. Andrews, A. E. Marciscano, C. G. Drake, and D. A. A. Vignali, “LAG3 (CD223) as a Cancer Immunotherapy Target,” Immunological Reviews 276, no. 1 (2017): 80–96.
M. Zettl, M. Wurm, O. Schaaf, et al., “Combination of Two Novel Blocking Antibodies, Anti‐PD‐1 Antibody Ezabenlimab (BI 754091) and Anti‐LAG‐3 Antibody BI 754111, Leads to Increased Immune Cell Responses,” Oncoimmunology 11, no. 1 (2022).
E. Burova, A. Hermann, J. Dai, et al., “Preclinical Development of the Anti‐LAG‐3 Antibody REGN3767: Characterization and Activity in Combination With the Anti‐PD‐1 Antibody Cemiplimab in Human PD‐1xLAG‐3‐Knockin Mice,” Molecular Cancer Therapeutics 18, no. 11 (2019): 2051–2062.
M. J. Oborski, C. M. Laymon, F. S. Lieberman, and J. M. Mountz, “Distinguishing Pseudoprogression From Progression in High‐Grade Gliomas: A Brief Review of Current Clinical Practice and Demonstration of the Potential Value of 18F‐FDG PET,” Clinical Nuclear Medicine 38, no. 5 (2013): 381–384.
X. Zhou, J. Jiang, X. Yang, et al., “First‐in‐Humans Evaluation of a PD‐L1‐Binding Peptide PET Radiotracer in Non‐Small Cell Lung Cancer Patients,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 63, no. 4 (2022): 536–542.
F. Bensch, E. L. van der Veen, M. N. Lub‐de Hooge, et al., “Zr‐Atezolizumab Imaging as a Non‐Invasive Approach to Assess Clinical Response to PD‐L1 Blockade in Cancer,” Nature Medicine 24, no. 12 (2018): 1852–1858.
L. N. Broer, D. G. Knapen, F. V. Suurs, et al., “89Zr‐3,2‐HOPO‐Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin‐Targeted 227Th‐Conjugate Therapy in Mice,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 63, no. 11 (2022): 1715–1721.
L. E. Lamberts, M.‐v. der Houven, C. W. van Oordt, E. J. ter Weele, et al., “ImmunoPET With Anti‐Mesothelin Antibody in Patients With Pancreatic and Ovarian Cancer Before Anti‐Mesothelin Antibody‐Drug Conjugate Treatment,” Clinical Cancer Research 22, no. 7 (2016): 1642–1652.
M. Keyaerts, C. Xavier, J. Heemskerk, et al., “Phase I Study of 68Ga‐HER2‐Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 57, no. 1 (2016): 27–33.
J. McGale, S. Khurana, A. Huang, et al., “PET/CT and SPECT/CT Imaging of HER2‐Positive Breast Cancer,” Journal of Clinical Medicine 12, no. 15 (2023): 4882.
G. A. Ulaner, J. A. Carrasquillo, C. C. Riedl, et al., “Identification of HER2‐Positive Metastases in Patients With HER2‐Negative Primary Breast Cancer by Using HER2‐Targeted 89Zr‐Pertuzumab PET/CT,” Radiology 296, no. 2 (2020): 370–378.
X. Guo, N. Zhou, Z. Chen, et al., “Construction of 124I‐Trastuzumab for Noninvasive PET Imaging of HER2 Expression: From Patient‐Derived Xenograft Models to Gastric Cancer Patients,” Gastric Cancer 23, no. 4 (2020): 614–626.
T. Liu, C. Liu, X. Xu, et al., “Preclinical Evaluation and Pilot Clinical Study of Al18F‐PSMA‐BCH for Prostate Cancer PET Imaging,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 60, no. 9 (2019): 1284–1292.
A. Mulgaonkar, R. Elias, L. Woolford, et al., “ImmunoPET Imaging With 89Zr‐Labeled Atezolizumab Enables in Vivo Evaluation of PD‐L1 in Tumorgraft Models of Renal Cell Carcinoma,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 28, no. 22 (2022): 4907–4916.
J. Chou, E. A. Egusa, S. Wang, et al., “Immunotherapeutic Targeting and PET Imaging of DLL3 in Small‐Cell Neuroendocrine Prostate Cancer,” Cancer Research 83, no. 2 (2023): 301–315.
E. C. F. Dijkers, J. G. W. Kosterink, A. P. Rademaker, et al., “Development and Characterization of Clinical‐Grade 89Zr‐Trastuzumab for HER2/neu immunoPET Imaging,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 50, no. 6 (2009): 974–981.
A.‐M. Chacko, C. Li, M. Nayak, et al., “Development of 124I Immuno‐PET Targeting Tumor Vascular TEM1/Endosialin,” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 55, no. 3 (2014): 500–507.
S. Wang, H. Zhu, Y. Li, et al., “First‐In‐Human DR5 PET Reveals Insufficient DR5 Expression in Patients With Gastrointestinal Cancer,” Journal for Immunotherapy of Cancer 9, no. 7 (2021): e002926.